Clinical Trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to investigate the safety, tolerability and pharmacokinetic characteristics of KR23248 capsules in healthy subjects. This study will be conducted in China. It will enroll male and female participants aged 18 years to 45 years.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-05-16
Trial Details
NCT Number NCT07585383
Lead Sponsor Jiangxi Kvvit Pharmaceutical Co., Ltd.
Conditions Schizophrenia
Enrollment 66 participants
Start Date 2026-05-19
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-15